Bioxytran鈥檚 Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
Bioxytran (OTCQB: BIXT) has announced significant progress in developing ProLectin-M, its broad-spectrum antiviral drug. The company has completed dosing in its dose optimization clinical trial, marking a crucial milestone in the drug's development.
ProLectin-M targets galectin fold on viral spike proteins and has shown impressive clinical results: 100% response rate (negative PCR tests) by day 7 and 88% response rate by day 3 in double-blinded placebo-controlled trials. The drug has demonstrated effectiveness against SARS-CoV-2, influenza, and RSV, with no viral rebounds during the 14-day observation period.
The drug's development, supported by an active FDA IND application, utilizes proprietary linear complex carbohydrate structures designed with nuclear magnetic resonance and AI to neutralize viral infectiousness.
Bioxytran (OTCQB: BIXT) ha annunciato notevoli progressi nello sviluppo di ProLectin-M, il suo farmaco antivirale ad ampio spettro. L'azienda ha completato la somministrazione nel trial clinico di ottimizzazione del dosaggio, segnando una tappa fondamentale nello sviluppo del farmaco.
ProLectin-M agisce sul galectin fold delle proteine spike virali e ha mostrato risultati clinici impressionanti: 100% di risposta (test PCR negativi) entro il giorno 7 e 88% di risposta entro il giorno 3 in studi clinici in doppio cieco controllati con placebo. Il farmaco si 猫 dimostrato efficace contro SARS-CoV-2, influenza e RSV, senza ricadute virali durante il periodo di osservazione di 14 giorni.
Lo sviluppo del farmaco, supportato da una domanda IND attiva presso la FDA, utilizza strutture proprietarie di carboidrati complessi lineari progettate con risonanza magnetica nucleare e intelligenza artificiale per neutralizzare l'infettivit脿 virale.
Bioxytran (OTCQB: BIXT) ha anunciado avances significativos en el desarrollo de ProLectin-M, su medicamento antiviral de amplio espectro. La compa帽铆a ha completado la dosificaci贸n en su ensayo cl铆nico de optimizaci贸n de dosis, marcando un hito crucial en el desarrollo del f谩rmaco.
ProLectin-M se dirige al plegamiento de galectina en las prote铆nas spike virales y ha mostrado resultados cl铆nicos impresionantes: 100% de tasa de respuesta (pruebas PCR negativas) para el d铆a 7 y 88% de tasa de respuesta para el d铆a 3 en ensayos controlados con placebo y doble ciego. El medicamento ha demostrado efectividad contra SARS-CoV-2, influenza y RSV, sin rebotes virales durante el per铆odo de observaci贸n de 14 d铆as.
El desarrollo del medicamento, respaldado por una solicitud activa de IND ante la FDA, utiliza estructuras propietarias de carbohidratos complejos lineales dise帽adas con resonancia magn茅tica nuclear e inteligencia artificial para neutralizar la infectividad viral.
Bioxytran (OTCQB: BIXT)電� 甏戨矓鞙� 頃皵鞚措煬鞀れ牅鞚� ProLectin-M 臧滊皽鞐愳劀 欷戩殧頃� 歆勳爠鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞖╇焿 斓滌爜頇� 鞛勳儊鞁滍棙鞐愳劀 韴棳毳� 鞕勲頃橃棳 鞎诫 臧滊皽鞚� 欷戩殧頃� 鞚挫爼響滊ゼ 靹胳洜鞀惦媹雼�.
ProLectin-M鞚� 氚旍澊霟姢 鞀ろ寣鞚错伂 雼氨歆堨潣 臧堧爥韹� 鞝戫灅 攵�鞙勲ゼ 響滌爜鞙茧 頃橂┌, 鞛勳儊 鞁滍棙鞐愳劀 7鞚� 彀棎 100% 氚橃潙毳�(鞚岇劚 PCR 瓴�靷�)瓿� 3鞚� 彀棎 88% 氚橃潙毳�鞚� 氤挫榾鞀惦媹雼�(鞚挫 毵龟瞼 鞙勳暯 雽�臁� 鞁滍棙). 鞚� 鞎诫鞚� SARS-CoV-2, 鞚疙攲耄棓鞛�, RSV鞐� 雽�頃� 須臣毳� 鞛呾頄堨溂氅� 14鞚� 甏�彀� 旮瓣皠 霃欖晥 氚旍澊霟姢 鞛皽鞚� 鞐嗢棃鞀惦媹雼�.
FDA IND 鞁犾箔鞚� 頇滌劚頇旊悳 靸來儨鞐愳劀 臧滊皽霅� 鞚� 鞎诫鞚� 頃奠瀽旮� 瓿惦獏瓿� 鞚戈车歆�電レ潉 鞚挫毄頃� 靹り硠霅� 霃呾爯鞝侅澑 靹犿槙 氤淀暕 韮勳垬頇旊 甑“毳� 頇滌毄頃橃棳 氚旍澊霟姢 臧愳椉霠レ潉 氍措牓頇旐暕雼堧嫟.
Bioxytran (OTCQB : BIXT) a annonc茅 des progr猫s significatifs dans le d茅veloppement de ProLectin-M, son m茅dicament antiviral 脿 large spectre. La soci茅t茅 a achev茅 le dosage dans son essai clinique d鈥檕ptimisation de la dose, marquant une 茅tape cruciale dans le d茅veloppement du m茅dicament.
ProLectin-M cible le repliement de la galectine sur les prot茅ines de pointe virales et a montr茅 des r茅sultats cliniques impressionnants : taux de r茅ponse de 100 % (tests PCR n茅gatifs) au jour 7 et taux de r茅ponse de 88 % au jour 3 lors d鈥檈ssais en double aveugle contr么l茅s par placebo. Le m茅dicament a d茅montr茅 son efficacit茅 contre SARS-CoV-2, la grippe et le VRS, sans rebonds viraux pendant la p茅riode d鈥檕bservation de 14 jours.
Le d茅veloppement du m茅dicament, soutenu par une demande IND active aupr猫s de la FDA, utilise des structures propri茅taires de glucides complexes lin茅aires con莽ues gr芒ce 脿 la r茅sonance magn茅tique nucl茅aire et 脿 l鈥檌ntelligence artificielle pour neutraliser l鈥檌nfectiosit茅 virale.
Bioxytran (OTCQB: BIXT) hat bedeutende Fortschritte bei der Entwicklung von ProLectin-M, seinem Breitband-Antiviral, bekannt gegeben. Das Unternehmen hat die Dosierung in seiner Dosisoptimierungs-Studie abgeschlossen, was einen wichtigen Meilenstein in der Entwicklung des Medikaments darstellt.
ProLectin-M zielt auf die Galectin-Faltung der viralen Spike-Proteine ab und zeigte beeindruckende klinische Ergebnisse: 100% Ansprechrate (negative PCR-Tests) bis Tag 7 und 88% Ansprechrate bis Tag 3 in doppelblinden, placebokontrollierten Studien. Das Medikament zeigte Wirksamkeit gegen SARS-CoV-2, Influenza und RSV, ohne virale R眉ckf盲lle w盲hrend des 14-t盲gigen Beobachtungszeitraums.
Die Entwicklung des Medikaments, unterst眉tzt durch einen aktiven FDA IND-Antrag, nutzt propriet盲re lineare komplexe Kohlenhydratstrukturen, die mit Kernspinresonanz und KI entworfen wurden, um die Virulenz zu neutralisieren.
- Completed dose optimization clinical trial with promising results
- 100% response rate by day 7 and 88% by day 3 in clinical trials
- Broad-spectrum effectiveness against multiple respiratory viruses
- Active IND application with FDA
- No viral rebounds observed during 14-day observation period
- Still in clinical development phase, not yet FDA approved
- Trading on OTCQB market rather than major exchange
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA
BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the 鈥淐ompany鈥�), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce significant progress in development of its broad-spectrum antiviral drug, ProLectin-M. The company has successfully completed dosing of its dose optimization clinical trial, bringing it one step closer to introducing a groundbreaking oral antiviral that could redefine the treatment landscape for respiratory infections, potentially reducing the need for traditional vaccinations.
ProLectin-M, Bioxytran鈥檚 leading drug candidate, targets the galectin fold on the spike proteins of viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Peer-reviewed published studies have demonstrated its ability to neutralize these viruses with high efficacy, achieving a complete response (negative PCR tests) in all subjects by day 7 and an
鈥淭his is a pivotal moment for Bioxytran and the field of virology,鈥� said Dr. David Platt, CEO of Bioxytran. 鈥淥ur broad-spectrum antiviral platform exploits conserved target regions present on the spike proteins that allows our linear complex carbohydrate molecules designed with the aid of nuclear magnetic resonance and artificial intelligence to neutralize the virus鈥檚 infectiousness. We have the potential to neutralize a wide range of respiratory viruses, including those that mutate rapidly. ProLectin-M will fundamentally change how we combat respiratory infections. The timing of this advancement aligns with a significant shift in U.S. health policy.鈥�
鈥淲e believe the redirection of resources away from mRNA vaccines creates a unique opportunity for Bioxytran,鈥� said Dr. Leslie Ajayi, Bioxytran鈥檚 Chief Medical Officer. 鈥淥ur data suggests ProLectin-M could become a first-line therapy for respiratory patients with no underlying medical conditions.
Bioxytran鈥檚 platform, rooted in the emerging field of Glycovirology, leverages proprietary linear complex carbohydrate chemical structures to block galectins, proteins that facilitate viral attachment to host cells. In vitro studies have shown ProLectin-M鈥檚 potential to neutralize not only SARS-CoV-2 but also influenza and RSV, with ongoing research exploring its efficacy against other viruses like Epstein-Barr Virus (EBV).
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing linear complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for stroke treatment. When utilized an FDA approved device to detect tissue oxygenationat the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over
Investor Relations
Michael Sheikh
509-991-0245
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran鈥檚 actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company鈥檚 Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What are the clinical trial results for Bioxytran's ProLectin-M antiviral drug?
Which viruses can Bioxytran's ProLectin-M target?
How does Bioxytran's ProLectin-M antiviral drug work?
What is the current development status of BIXT's ProLectin-M?
Who is leading Bioxytran's ProLectin-M development?
